Investigators at Weill Cornell Medicine have assembled the most comprehensive atlas to date of messenger RNA (mRNA) variants in the mouse and human brain. The atlas is an important new resource in understanding brain development, neuron specialization and other brain functions.
May 2024 EIPM Director's Monthly Newsletter
May 10, 2024
Dear Members of the Englander Institute,
Thank you all for a very productive April!
GoT-ChA: A New Tool for Detailing How Gene Mutations Affect Cells
May 9, 2024
A team co-led by researchers at Weill Cornell Medicine and the New York Genome Center has developed an advanced method for revealing how gene mutations disrupt the normal packaging of DNA. These structural changes, which alter patterns of gene activity in a cell, are known as epigenetic changes and can lead to malignancy.
Melanoma Monday: From Early Detection to Cutting-Edge Treatments
May 6, 2024
Melanoma, the deadliest form of skin cancer, is on the rise. But there's a silver lining as this increase might be partly due to earlier detection. The use of Dermoscopy, a handheld device which allows closer surveillance of the organization of a mole or lesion, has greatly facilitated in detection of melanomas and moles that are dysplastic/or atypical. This device allows doctors to see the intricate structure of moles, helping identify suspicious ones.
Ongoing Research Shows Promising Results for Neoadjuvant Treatment for Colorectal Cancer
April 10, 2024
Historically, immunotherapy has demonstrated limited effectiveness in a significant majority of patients with colorectal cancer.
Dr. Bishoy Faltas Named Chief Research Officer of the Englander Institute for Precision Medicine
March 29, 2024
I am excited to announce Dr. Bishoy M. Faltas has been named Chief Research Officer of the Englander Institute for Precision Medicine (EIPM), effective immediately.
Ongoing Research Shows Promising Results for Neoadjuvant Treatment for Colorectal Cancer
March 28, 2024
Historically, immunotherapy has demonstrated limited effectiveness in a significant majority of patients with colorectal cancer.
Mapping the Evolution of Urinary Tract Cancer Cells
March 18, 2024
Researchers at Weill Cornell Medicine have performed the most comprehensive analysis to date of cancer of the ureters or the urine-collection cavities in the kidney, known as upper tract urothelial carcinoma (UTUC). The study, which compared the characteristics of primary and metastatic tumors, provides new insights into the biology of these aggressive cancers and potential ways to treat them.
EIPM Researchers Earn Cancer Grand Challenges Funding Award to Study Cancer Inequity
March 6, 2024
Weill Cornell Medicine is part of an international team that has been awarded funding of up to $25 million over five years by Cancer Grand Challenges to study the causes of cancer inequities.
Deciphering the Male Breast Cancer Genome
March 5, 2024
Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets, according to a study by Weill Cornell Medicine investigators. They have conducted the first whole genome sequencing analysis of male breast cancer, which looked at the complete DNA landscape of tumor samples from 10 patients.